AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence.
This article describes in detail the preclinical science leading to the creation of the AE37 vaccine and examines use of this agent in multiple clinical trials for breast and prostate cancer. The safety profile of AE37 is discussed and opinions on the potential of the vaccine in breast and prostate cancer patient subsets along with other malignancies, are offered. Expert Opinion: Future trials utilizing the AE37 vaccine to treat other HER2-expressing malignancies are likely to see similar success, and this will be enhanced by combination immunotherapy. Ii-Key modification of other peptides of interest across oncology and virology could yield impressive results over the longer term.
PMID: 33191799 [PubMed - as supplied by publisher]
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | Drugs & Pharmacology | HER2 | Herceptin | Immunotherapy | Prostate Cancer | Science | Vaccines | Virology